Ravi Theja Kambhampati, V. Invitae Corporation

Court of Appeals of Washington·Decided August 24, 2026·No. 87805-1·Unpublished

Opinion

IN THE COURT OF APPEALS OF THE STATE OF WASHINGTON

RAVI THEJA KAMBHAMPATI, individually, and MEGHANA No. 87805-1-I SEETHAMRAJU, individually, and as guardian ad litem for ACHYUTH DIVISION ONE KAMBHAMPATI, a minor, UNPUBLISHED OPINION

Appellants,

v.

INVITAE CORPORATION, a foreign corporation,

Respondent,

HAZELRIGG, C.J. — Ravi Kambhampati and Meghana Seethamraju appeal from the trial court’s summary judgment order that dismissed their suit against Invitae Corporation after it concluded that they had failed to present sufficient evidence to support the elements of their claim for negligence. The trial court erred when it so concluded, and we reverse and remand.

FACTS

Ravi Kambhampati and Meghana Seethamraju (collectively Kambhampati)

filed a complaint for medical negligence against Invitae Corporation on February 1, 2023 individually and, as to Seethamraju, in her capacity as guardian ad litem for their minor son, A. Their complaint alleged that Invitae negligently omitted certain genetic variant results from their prenatal genetic carrier screening that the

laboratory conducted for Seethamraju. Their complaint alleged that both they and A suffered general and special damages as a result of Invitae’s medical negligence.

One and a half years earlier, in June 2021, testing of Kambhampati’s newborn son, A, established that he had been born with a rare genetic condition known as X-ALD, X-linked adrenoleukodystrophy, that has a high likelihood of manifesting in a variety of significant symptoms at different ages. According to Invitae’s genetic carrier screening results,

X-linked adrenoleukodystrophy (X-ALD) is a condition that causes progressive deterioration of the nervous system and the adrenal glands (small glands located on top of each kidney). In affected individuals, the ability of the nerves to relay information to the brain is reduced because the myelin, which is the fatty covering that insulates nerves in the central nervous system, is prone to deterioration (demyelination). Additionally, damage to the outer layer of the adrenal glands (adrenal cortex) and the subsequent shortage of various adrenal hormones (adrenocortical insufficiency, or Addison’s disease)

causes symptoms such as weakness, weight loss, vomiting, and coma. The cerebral form of X-ALD (cerebral adrenoleukodystrophy)

usually presents in childhood. Symptoms typically include progressive learning disabilities and behavior problems, as well as vision and hearing problems. Most individuals also have impaired adrenocortical function. The adrenomyeloneuropathy form of X-ALD typically presents in early to middle adulthood. Symptoms often include progressive stiffness, weakness, or paralysis of the lower limbs (paraparesis), urinary tract disorders, and impaired adrenocortical function. Other affected individuals have Addison’s disease only, although many develop symptoms of the adrenomyeloneuropathy form by middle age. Symptoms and severity can vary, even between family members with the same genetic change. Life expectancy is dependent on the severity of symptoms.

X-ALD primarily affects males. . . . Females typically present at a later age than males and only rarely develop adrenocortical insufficiency or cerebral adrenoleukodystrophy. Follow-up depends on each affected individual’s specific situation, and discussion with a healthcare provider should be considered, and typically includes

corticosteroid replacement therapy for individuals with adrenal insufficiency.

(Emphasis added.)

This was notable because a prenatal screening report that the couple received from Invitae six months earlier, in December 2020, did not note the presence of the genetic variant associated with X-ALD. Invitae contended that this omission was due to its prior determination that the genetic variant detected by the screening was a “Variant of Uncertain Significance” (VUS). This determination, Invitae explained, was based on the Standards and Guidelines for the Interpretation of Sequence Variants: a Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP 2015 guidelines), which provides that “[g]enetic variants are classified as either benign, likely benign, pathogenic, likely pathogenic, or VUS.” Kambhampati’s complaint alleged that the variant should have been reported as “likely pathogenic” and Invitae’s failure to report it as such in its prenatal screening report, rather than in its newborn screening report, constituted negligence.

Shortly after Kambhampati’s complaint was filed in February 2023, Invitae filed for Chapter 11 bankruptcy, and this case was stayed on that basis. The trial court orally granted a motion to lift the stay a year and a half later, in August 2024, and subsequently entered an amended case scheduling order. 1 Roughly six months after that, in January 2025, Invitae moved for summary judgment dismissal

1 The case scheduling order is not included in the record on appeal but is referenced by

the trial court in its order on summary judgment, and neither party disputes this characterization of the procedural history of the case.

on the bases that it had not breached any duty owed and Kambhampati had no recoverable damages for either of their proffered theories of reproductive medical negligence. Though not transmitted to this court, the record reflects that Kambhampati filed a response in opposition to the motion for summary judgment, along with supporting declarations, including that of an expert witness. 2 Shortly after Invitae filed its reply in support of summary judgment, it separately moved to exclude portions of Kambhampati’s expert opinion testimony, and both parties submitted supplemental briefing.

The trial court denied Invitae’s motion to exclude Kambhampati’s expert after specifically concluding that their expert was qualified to opine on standard of care and breach but nevertheless granted Invitae’s motion for summary judgment and dismissed the matter with prejudice. Notably, in describing the bases on which the court determined that Kambhampati failed to establish a prima facie case in support of their negligence claims, the court’s written order indicated only that “there is no dispute of material fact that [Kambhampati] cannot meet their burden to establish elements of their claims, and Invitae is entitled to judgment as a matter of law.”

Kambhampati and Seethamraju timely appealed.

ANALYSIS

Kambhampati present two assignments of error: that the trial court erred when it dismissed their action on summary judgment and when it did not

2 While the response was not transmitted, the declarations and evidence that Kambhampati submitted with their response are present in the record before us.

“completely strik[e] the untimely factual ‘Supplemental Declaration’ [of geneticist Dr. Heidi Rehm] and in considering it for any purpose.” As to their assignment of error to summary judgment dismissal, we agree.

I. Scope of Appeal As a preliminary matter, the record plainly establishes that the trial court did not consider for any purpose the supplemental Rehm declaration referenced in Kambhampati’s second assignment of error by the trial court. The express language of the order on summary judgment states,

Submitting additional facts and new arguments after oral argument is not timely. The [c]ourt will consider the cases cited by the parties in the supplemental materials, as the [c]ourt considers legal authority relevant to the motion submitted to the [c]ourt. The [c]ourt will not consider the supplemental declaration . . . or any new facts in arguments submitted by the parties in their supplemental materials.

Free access — add to your briefcase to read the full text and ask questions with AI

Ravi Theja Kambhampati, V. Invitae Corporation, (Wash. Ct. App. 2026).

Ravi Theja Kambhampati, V. Invitae Corporation (Ravi Theja Kambhampati, V. Invitae Corporation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Young v. Key Pharmaceuticals, Inc.
770 P.2d 182 (Washington Supreme Court, 1989)
Ball v. Mudge
391 P.2d 201 (Washington Supreme Court, 1964)
McKernan v. Aasheim
687 P.2d 850 (Washington Supreme Court, 1984)
Rieck v. Medical Protective Co.
219 N.W.2d 242 (Wisconsin Supreme Court, 1974)
Harbeson v. Parke-Davis, Inc.
656 P.2d 483 (Washington Supreme Court, 1983)
Womack v. Von Rardon
135 P.3d 542 (Court of Appeals of Washington, 2006)
Oliver L. Wuth v. Valley Medical Center And Labcor
189 Wash. App. 660 (Court of Appeals of Washington, 2015)
Dyal v. Fire Companies Adjustment Bureau, Inc.
161 P.2d 321 (Washington Supreme Court, 1945)
Womack v. Von Rardon
133 Wash. App. 254 (Court of Appeals of Washington, 2006)
Frye v. United States
293 F. 1013 (D.C. Circuit, 1923)